VR Adviser, LLC Increases Stake in Spyre Therapeutics by 1 Million Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 21 hours ago
0mins
Should l Buy SYRE?
Source: NASDAQ.COM
- Share Increase: On February 17, 2026, VR Adviser, LLC disclosed the purchase of 1 million shares of Spyre Therapeutics, with an estimated trade value of $25.78 million based on quarterly average pricing, indicating strong confidence in the biotech firm.
- Value Growth: As of December 31, 2025, VR Adviser's total holding in Spyre Therapeutics reached $120.74 million, reflecting an increase of $75.73 million from the previous quarter, driven by both trading activity and share price appreciation.
- Portfolio Significance: Spyre Therapeutics now represents 5.96% of VR Adviser's 27-position U.S. equity portfolio, highlighting its importance within the fund, particularly under a strategy focused on biotechnology investments.
- Market Competitiveness: As a preclinical-stage biotechnology company, Spyre Therapeutics specializes in developing novel antibody therapies for inflammatory bowel disease, aiming to address significant unmet medical needs in gastrointestinal health, which positions it for long-term value creation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SYRE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SYRE
Wall Street analysts forecast SYRE stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 43.060
Low
40.00
Averages
56.67
High
70.00
Current: 43.060
Low
40.00
Averages
56.67
High
70.00
About SYRE
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VR Adviser, LLC Increases Stake in Spyre Therapeutics by 1 Million Shares
- Share Increase: On February 17, 2026, VR Adviser, LLC disclosed the purchase of 1 million shares of Spyre Therapeutics, with an estimated trade value of $25.78 million based on quarterly average pricing, indicating strong confidence in the biotech firm.
- Value Growth: As of December 31, 2025, VR Adviser's total holding in Spyre Therapeutics reached $120.74 million, reflecting an increase of $75.73 million from the previous quarter, driven by both trading activity and share price appreciation.
- Portfolio Significance: Spyre Therapeutics now represents 5.96% of VR Adviser's 27-position U.S. equity portfolio, highlighting its importance within the fund, particularly under a strategy focused on biotechnology investments.
- Market Competitiveness: As a preclinical-stage biotechnology company, Spyre Therapeutics specializes in developing novel antibody therapies for inflammatory bowel disease, aiming to address significant unmet medical needs in gastrointestinal health, which positions it for long-term value creation.
See More
VR Adviser Increases Stake in Spyre Therapeutics by 1 Million Shares
- Share Acquisition: On February 17, 2026, VR Adviser, LLC disclosed the purchase of 1 million shares in Spyre Therapeutics, valued at approximately $25.78 million, reflecting the firm's confidence in the biotech company.
- Value Appreciation: As of December 31, 2025, VR Adviser's total holdings in Spyre reached 3,685,448 shares, valued at $120.74 million, with a quarter-end increase of $75.73 million, showcasing the dual impact of share price appreciation and trading activity.
- Portfolio Significance: Spyre Therapeutics now represents 5.96% of VR Adviser's reportable U.S. equity assets, highlighting its strategic importance within the firm's 27-position portfolio in the biotech sector.
- Strong Market Performance: As of March 18, 2026, Spyre's share price stood at $43.03, reflecting a 132.1% increase over the past year, significantly outperforming the S&P 500 by 115.4%, indicating robust market performance and investment appeal.
See More
VR Adviser, LLC Reduces Stake in Ocular Therapeutix
- Share Reduction Details: On February 17, 2026, VR Adviser, LLC disclosed the sale of 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $70.96 million, indicating a potential decline in confidence in the stock.
- Asset Management Impact: This transaction reduced Ocular Therapeutix's share of VR Adviser's reportable assets under management to 4.39%, with a holding value of $88.81 million, reflecting a diminished significance in the fund's portfolio.
- Market Performance Analysis: As of February 17, 2026, Ocular Therapeutix shares were priced at $6.99, down 3.98% over the past year, underperforming the S&P 500 by 15.90 percentage points, suggesting low market expectations for future growth.
- Investor Considerations: While the reduction is a routine portfolio management action, Ocular Therapeutix's product DEXTENZA and its drug delivery technology offer differentiation in a competitive ophthalmology market, warranting investor attention on its future market expansion and revenue growth potential.
See More
VR Adviser, LLC Sells Shares of Ocular Therapeutix
- Share Sale Overview: On February 17, 2026, VR Adviser, LLC disclosed to the SEC that it sold 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $71.01 million, reducing its stake in the company to 4.4%.
- Asset Management Impact: The sale resulted in a $65.05 million decrease in the value of VR Adviser's position, highlighting the direct impact of trading and stock price fluctuations on its assets under management during the fourth quarter.
- Portfolio Adjustment: This transaction represented 3.51% of VR Adviser's reportable assets under management, indicating routine portfolio management adjustments within its strategy of concentrated investments in small-cap biotech firms.
- Market Performance Analysis: Ocular Therapeutix's stock has declined approximately 4% over the past year and has underperformed the S&P 500 by about 16 points, reflecting uneven growth in a competitive ophthalmic pharmaceutical market, which may affect investor confidence.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting strong confidence in the company.
- Asset Management Proportion: Savara's shares account for 4.1% of VR Adviser's over $2 billion in assets under management, indicating its significance in the firm's portfolio and potential influence on future investment decisions.
- Market Potential: Savara focuses on developing inhaled biologics for rare respiratory diseases, and although it currently lacks approved products, its lead candidate, molgramostim, is in late-stage trials and aims to address significant unmet medical needs, suggesting long-term market potential.
- Investment Risks: While Savara's stock surged 96.4% last year, investors should be aware of the high-risk nature of the biotech industry, as Savara has no revenue-generating products, making its future stock performance heavily reliant on regulatory approvals and potential revenue from its lead drug candidate.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting confidence in Savara's future performance.
- AUM Proportion: Savara represents 4.1% of VR Adviser's total assets under management, highlighting its strategic significance among the firm's 27 positions and indicating a strong belief in the company's potential.
- Market Performance: Savara's stock gained 96.4% in 2022, leading investors to maintain an optimistic outlook for continued growth, particularly with expectations for 2025's performance.
- Risk Advisory: While Savara shows promise in the biotech sector, the lack of approved products and current revenue generation necessitates caution from investors due to the inherent high-risk nature of the investment.
See More
VR Adviser, LLC Increases Stake in Spyre Therapeutics by 1 Million Shares
- Share Increase: On February 17, 2026, VR Adviser, LLC disclosed the purchase of 1 million shares of Spyre Therapeutics, with an estimated trade value of $25.78 million based on quarterly average pricing, indicating strong confidence in the biotech firm.
- Value Growth: As of December 31, 2025, VR Adviser's total holding in Spyre Therapeutics reached $120.74 million, reflecting an increase of $75.73 million from the previous quarter, driven by both trading activity and share price appreciation.
- Portfolio Significance: Spyre Therapeutics now represents 5.96% of VR Adviser's 27-position U.S. equity portfolio, highlighting its importance within the fund, particularly under a strategy focused on biotechnology investments.
- Market Competitiveness: As a preclinical-stage biotechnology company, Spyre Therapeutics specializes in developing novel antibody therapies for inflammatory bowel disease, aiming to address significant unmet medical needs in gastrointestinal health, which positions it for long-term value creation.
See More
VR Adviser Increases Stake in Spyre Therapeutics by 1 Million Shares
- Share Acquisition: On February 17, 2026, VR Adviser, LLC disclosed the purchase of 1 million shares in Spyre Therapeutics, valued at approximately $25.78 million, reflecting the firm's confidence in the biotech company.
- Value Appreciation: As of December 31, 2025, VR Adviser's total holdings in Spyre reached 3,685,448 shares, valued at $120.74 million, with a quarter-end increase of $75.73 million, showcasing the dual impact of share price appreciation and trading activity.
- Portfolio Significance: Spyre Therapeutics now represents 5.96% of VR Adviser's reportable U.S. equity assets, highlighting its strategic importance within the firm's 27-position portfolio in the biotech sector.
- Strong Market Performance: As of March 18, 2026, Spyre's share price stood at $43.03, reflecting a 132.1% increase over the past year, significantly outperforming the S&P 500 by 115.4%, indicating robust market performance and investment appeal.
See More
VR Adviser, LLC Reduces Stake in Ocular Therapeutix
- Share Reduction Details: On February 17, 2026, VR Adviser, LLC disclosed the sale of 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $70.96 million, indicating a potential decline in confidence in the stock.
- Asset Management Impact: This transaction reduced Ocular Therapeutix's share of VR Adviser's reportable assets under management to 4.39%, with a holding value of $88.81 million, reflecting a diminished significance in the fund's portfolio.
- Market Performance Analysis: As of February 17, 2026, Ocular Therapeutix shares were priced at $6.99, down 3.98% over the past year, underperforming the S&P 500 by 15.90 percentage points, suggesting low market expectations for future growth.
- Investor Considerations: While the reduction is a routine portfolio management action, Ocular Therapeutix's product DEXTENZA and its drug delivery technology offer differentiation in a competitive ophthalmology market, warranting investor attention on its future market expansion and revenue growth potential.
See More
VR Adviser, LLC Sells Shares of Ocular Therapeutix
- Share Sale Overview: On February 17, 2026, VR Adviser, LLC disclosed to the SEC that it sold 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $71.01 million, reducing its stake in the company to 4.4%.
- Asset Management Impact: The sale resulted in a $65.05 million decrease in the value of VR Adviser's position, highlighting the direct impact of trading and stock price fluctuations on its assets under management during the fourth quarter.
- Portfolio Adjustment: This transaction represented 3.51% of VR Adviser's reportable assets under management, indicating routine portfolio management adjustments within its strategy of concentrated investments in small-cap biotech firms.
- Market Performance Analysis: Ocular Therapeutix's stock has declined approximately 4% over the past year and has underperformed the S&P 500 by about 16 points, reflecting uneven growth in a competitive ophthalmic pharmaceutical market, which may affect investor confidence.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting strong confidence in the company.
- Asset Management Proportion: Savara's shares account for 4.1% of VR Adviser's over $2 billion in assets under management, indicating its significance in the firm's portfolio and potential influence on future investment decisions.
- Market Potential: Savara focuses on developing inhaled biologics for rare respiratory diseases, and although it currently lacks approved products, its lead candidate, molgramostim, is in late-stage trials and aims to address significant unmet medical needs, suggesting long-term market potential.
- Investment Risks: While Savara's stock surged 96.4% last year, investors should be aware of the high-risk nature of the biotech industry, as Savara has no revenue-generating products, making its future stock performance heavily reliant on regulatory approvals and potential revenue from its lead drug candidate.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting confidence in Savara's future performance.
- AUM Proportion: Savara represents 4.1% of VR Adviser's total assets under management, highlighting its strategic significance among the firm's 27 positions and indicating a strong belief in the company's potential.
- Market Performance: Savara's stock gained 96.4% in 2022, leading investors to maintain an optimistic outlook for continued growth, particularly with expectations for 2025's performance.
- Risk Advisory: While Savara shows promise in the biotech sector, the lack of approved products and current revenue generation necessitates caution from investors due to the inherent high-risk nature of the investment.
See More
